Moving forward in melanoma, adding a feedback inhibitor, such as SHP2, may improve outcomes in BRAF V600E-mutant patients, as may the combination of a RAF dimer inhibitor plus MEK inhibitor in RAS Q61X-mutant melanoma. This evidence concerns the gene MAP2K7 and melanoma.